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CardioprotectionSigma-1 receptors are ligand-regulated chaperone proteins, involved in several cellular mechanisms. The
aim of this systematic review was to examine the effects that the sigma-1 receptor has on the cardiovas-
cular system. The interaction targets and proposed mechanisms of action of sigma-1 receptors were
explored, with the aim of determining if the sigma-1 receptor is a potential pharmacological target for
cardiac pathologies. This systematic review was conducted according to the PRISMA guidelines and these
were used to critically appraise eligible studies. Pubmed and Scopus were systematically searched for
articles investigating sigma-1 receptors in the cardiovascular system. Papers identified by the search
terms were then subject to analysis against pre-determined inclusion criteria. 23 manuscripts met the
inclusion criteria and were included in this review. The experimental platforms, experimental techniques
utilised and the results of the studies were summarised. The sigma-1 receptor is found to be implicated in
cardioprotection, via various mechanisms including stimulating the Akt-eNOS pathway, and reduction of
Ca2+ leakage into the cytosol via modulating certain calcium channels. Sigma-1 receptors are also found
to modulate other cardiac ion channels including different subtypes of potassium and sodium channels
and have been shown to modulate intracardiac neuron excitability. The sigma-1 receptor is a potential
therapeutic target for treatment of cardiac pathologies, particularly cardiac hypertrophy. We therefore
suggest investigating the cardioprotective mechanisms of sigma-1 receptor function, alongside proposed
potential ligands that can stimulate these functions.
 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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the most common cause of death worldwide. In 2015, 25.2% of
female and 27.4% of male deaths in the United Kingdom werecaused by CVD, only second to cancer. Although incidences of
CVD have reduced four-fold since 1970, it is still a current problem
and an important disease which requires further intervention. CVD
is also burdening the National Health Service; in 2013/14, the NHS
spent four billion pounds on treatment and secondary care for
patients with CVD [1]. Management of CVD often involves a com-
bination of surgical and pharmacological treatments, which have
2 R. Lewis et al. / IJC Heart & Vasculature 26 (2020) 100449various limitations. Surgical intervention is often used to treat the
primary cause of disease, which has high associated surgical,
inpatient and discharge costs. Furthermore, the patient often
requires chronic drug administration to manage their condition
upon discharge [2].
Most drugs commonly prescribed for the treatment of CVD act
on specific receptor classes within the body, albeit not specifically
in the cardiovascular system. These include diuretics, b-
adrenoreceptor blockers, antihypertensive drugs, anti-anginals,
antiplatelet and lipid-lowering drugs [1]. Angiotensin-converting
enzymes have been shown to increase within coronary endothelial
cells and the valvular endothelium during vascular hypotension
[3,4]. ACE inhibitors (ACEi), such as benazepril, lower blood pres-
sure and promote cardiac remodelling mechanisms following a
myocardial infarction and acute/chronic heart failure [5]. However,
prolonged ACEi usage may promote iatrogenic renal failure due to
a lack of angiotensin II regulation of glomerular filtration rate, as
well as angioedema due to the production of excess bradykinins
[6]. Other drugs act on specific cellular receptors within the
cardiomyocyte. b-blockers such as propranolol bind
b-adrenoceptors, preventing the binding of adrenaline and nora-
drenaline to the receptor within the sino-atrial node (SAN) and
therefore diminish their sympathetic effect. This impairs subse-
quent Gs protein activation and calcium entry into the cell, reduc-
ing heart rate and contractility of the cells [7]. However, b-blockers
are contraindicated in patients with sinus bradycardia and have
been related to heart failure, AV-node block and hypotension when
used in high doses or for a prolonged period of time [8]. Clearly,
existing treatment options are insufficient or bring about unde-
sired side effects, warranting the need for the development of
novel therapeutics.
Given the prevalence and severity of CVD, and the need for
improved treatment options, an array of non-receptor channel con-
stituents and ion channels have been screened for treatment of dis-
eases. One such example is the sigma receptors (sigma-Rs). Sigma-
Rs are ligand-gated chaperone proteins, involved in protein folding
in the cell under physiological and stress conditions and binding of
non-native proteins within the body. There are two distinct
sub-types; Sigma-1R and Sigma-2R [9]. Sigma-1Rs are a 223
amino-acid length protein, found within the plasma membrane
and intracellularly in the nuclear membrane, endoplasmic reticu-
lum and mitochondrial-associated membrane [10]. They can
translocate from the endoplasmic reticulum to other intracellular
sites during increasing cellular stress. Sigma-1Rs possess two
transmembrane domains and two hydrophobic steroid binding
domain-like regions located on the C terminal of the receptor
[11]. Sigma-1Rs have been shown to have a role in a number
of cellular pathways, including ion channel activation, protein
kinase A activation, neurotransmitter release, inositol-3-
phosphate-mediated calcium-induced calcium release, and induc-
tion of cellular differentiation [12].
Sigma-1Rs have been widely studied in the CNS and have his-
torically been targeted for the treatment of depression and
schizophrenia with significant clinical improvements [13]. Sigma-
1Rs have been shown to be neuroprotective against excess calcium
currents in neurons. Specifically, they have been shown to play an
important role in regulating intracellular calcium concentrations
via mediation of L-type calcium channels, promoting or inhibiting
the release of neurotransmitter at the neuronal synapse. When
known sigma-1R agonists are applied, calcium currents via
voltage-gated calcium channels (VGCC) decrease [14]. The applica-
tion of such agonists with verapamil, a selective VGCC blocker,
showed no overall decrease in calcium currents, illustrating a rela-
tionship between sigma-1R activation and calcium channels [14].
Similarly, sigma-1R activation also seems to inhibit sodium influx
via GiPCR or the Nav1.5 channel without requiring ATP as aco-ligand. By inhibiting sodium channels, this results in a decreas-
ing action potential (AP) firing rate, delayed AP latency and longer
refractory periods. This seems to provide a protective mechanism
to prevent neuronal excitability, though the exact mechanism is
still unclear [15].
Recently, the endogenous molecule choline has been shown to
modulate sigma-1Rs. Choline is produced in cells by phospholipase
D from phosphatidylcholine and has been shown to activate sigma
1-Rs [16]. In doing so, it potentiates the calcium signals evoked by
inositol trisphosphate receptors (IP3Rs). Choline itself has been
described as a cardioprotective agent [17] and its ability to modu-
late sigma-1Rs may provide a mechanism for understanding this
effect.
While sigma-1Rs have been extensively studied in the CNS, they
have been found to be present inmultiple tissues, including the car-
diovascular system and the kidneys, among many others [18]. It is
interesting to note that the sigma-1R protein levels are higher in
heart tissue than brain tissue in rats [18]. The first report of
sigma-1R function in the heart showed that increased contractility
was mediated by sigma-1R ligands in cultured cardiomyocytes
from neonatal rats [19]. Subsequently, sigma-1R was detected in
the membranes of adult rat ventricular cardiomyocytes [20]. Fur-
ther studies using isolated rat cardiomyocyte preparations revealed
that 80% of sigma-Rs in rat ventricular myocardium are sigma-1Rs,
while the remaining 20% are sigma-2Rs [20]. As such, this review
will mainly focus on the potential cardioprotective role of sigma-
1Rs and their mechanism of action. We describe current studies
considering the impact of sigma-1R agonists in treating various car-
diac pathologies, including cardiac hypertrophy, and identify
opportunities for further development of sigma-1R agonists as
novel and safe therapeutic targets. In undertaking this critical
review, we aim to (1) Establish whether sigma-1Rs are a useful area
of study in cardiovascular science, (2) Describe the roles of sigma-
1R in the cardiovascular system, (3) Discuss current evidence for
sigma-1R as a therapeutic target in the heart, (4) Summarise
whether sigma-1R is a suitable target for pharmacological studies
into cardiovascular disease and suggest possible future directions.1. Research question and search strategy
Using the PICO structure (Population, Intervention, Comparator
and Outcomes), the following research question was formulated: Is
the Sigma-1R a potential pharmacological target for cardiac patholo-
gies? The Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) guidelines were then used to perform this
systematic review [21].
Two databases (PubMed and Scopus) were searched in Septem-
ber 2018. The search was performed using the terms ‘‘sigma-1
receptor” AND ‘‘cardiac” to obtain the primary list of papers from
each database. For PubMed, the MeSH terms applied are:
(‘‘sigma-1 receptor”[Supplementary Concept] OR ‘‘sigma-1 recep-
tor”[All Fields] OR ‘‘sigma 1 receptor”[All Fields]) AND (‘‘heart”
[MeSH Terms] OR ‘‘heart”[All Fields] OR ‘‘cardiac”[All Fields])
AND (‘‘1988/01/01”[PDAT] : ‘‘2018/12/31”[PDAT]). For Scopus, a
similar search was performed using the search terms ‘‘sigma-1
receptor” AND ‘‘cardiac” under ‘‘Article abstract, title, keywords”.2. Article selection and processing
Pre-defined inclusion and exclusion criteria were applied to the
journal title and journal abstract. For each of the databases, papers
were first excluded based on exclusion criteria of paper is not in
English or is not an original research paper (i.e. it is a review article,
editorial or book chapter). Next, the papers were screened for
inclusion. The inclusion criteria were specified as ‘‘the article
Fig. 1. Study attrition methodology Search was carried out on 2 databases: PubMed
and Scopus, in September 2018.
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organelles, channels and proteins present in the heart”. After the
search methodology had been defined, two independent members
of the review team independently screened the databases using
the search methodology to ensure that the same papers were
obtained. Full papers were then sourced from the database. If
unavailable, the authors were contacted via email to obtain the full
papers, or the papers were purchased from the journal publishers.3. Quality appraisal
The Checklist of Review Criteria established by the Task Force of
Academic Medicine and the GEA-RIME Committee [22] was used to
evaluate the quality of all included studies. Relevance of the study
was also a criteria in the quality appraisal, and this second screen-
ing of relevance is applied to the entire paper, while the previous
screening for inclusion was applied only to the paper title and
abstract. The search for ‘‘sigma-1 receptor” AND ‘‘cardiac” resulted
in 54 titles in PubMed and 36 in Scopus. After screening using the
inclusion and exclusion criteria, 23 papers were retrieved from
PubMed and 17 were retrieved from Scopus. Subsequently, dupli-
cates were removed, and a total of 23 papers remained that
focused on the role of Sigma-1R related to the heart. The search
attrition methodology and the number of papers that resulted from
each screening step is summarised in Fig. 1. The 23 papers were
subsequently put through the quality appraisal, with a total of 13
criteria being assessed. 22 out of 23 papers met at least 12 out of
13 criteria, reflecting adequate scientific robustness and relevance
for subsequent analysis (Table 1). Subsequently, the 22 papers
were included in the review, and the study characteristics of each
paper has been summarised (Table 2).4. Experimental platforms, techniques and results
In the identified studies, various experimental platforms have
been used to investigate the role of sigma-1R in relation to the
heart. Common platforms included over or under-expressing
sigma-1R, application of agonists or antagonists, and induction of
pathology (hypertrophy, ischaemia, etc). Application of sigma-1R
ligand (agonist and antagonist) was the most common platform
employed to study downstream effects of sigma-1R, with 77%
and 68% of papers applying a sigma-1R agonist and antagonist,
respectively (Fig. 2). Various experimental techniques were used,
including heart weight measurements, electrophysiological stud-
ies, haemodynamic measurements, gene and protein expression
studies, protein interaction studies and Ca2+ content assays
(Fig. 3). The most commonly used experimental technique was
studying protein expression via Western blotting, with 64% of
papers employing this technique. 11 papers demonstrated the role
of sigma-1R in cardioprotection. Specifically, 8 papers discussed
the cardioprotective role of sigma-1R against hypertrophy, while
2 papers discussed the cardioprotective role of sigma-1R against
apoptosis and cellular toxicity. Sigma-1R is proposed to play mod-
ulatory roles in the Akt-eNOS pathway, the ER stress response
pathway, to aid in restoration of IP3R-mediated mitochondrial
ATP production and reduce calcium leakage into the cytosol.
Sigma-1R is found to interact with various sodium, potassium
and calcium channels in cardiomyocytes, with implications for
arrhythmia, contractility, calcium handling and ATP production.
In addition, 2 papers also studied the role of Sigma-1R in intracar-
diac neurons, with implications for modulating cardiac function via
its effects on peripheral nervous system excitability.5. Sigma-1R and cardioprotection
Sigma-1Rs have been identified as having a role in cardioprotec-
tion against (i) hypertrophy, (ii) cellular toxicity/apoptosis, and (iii)
maladaptive ER stress response. The effects of sigma-1R on cardiac
hypertrophy have been extensively studied in both in vivo and
in vitro systems. Abdominal aortic stenosis and transverse aortic
constriction were commonly used to establish pressure-
overloading (PO), to induce cardiac hypertrophy in in vivo systems
[18,23–25]; while angiotensin-II stimulation was used to stimulate
cardiomyocyte hypertrophy in vitro [24]. The hormones 17b-
estradiol (E2) and dehydroepiandrosterone (DHEA), and drugs flu-
voxamine (a selective serotonin reuptake inhibitor (SSRI)) were
shown to activate sigma-1R in hypertrophic models [24–26]. It
was found that sigma-1R levels are decreased in hypertrophic
models, and treatment with sigma-1R agonists recovered sigma-
1R mRNA and protein expression, and led to cardioprotection, as
evidenced by better haemodynamic performance and reduced car-
diac hypertrophy [18,23–25]. Pre-treatment with sigma-1R siRNA
abolished fluvoxamine-mediated inhibition of CM hypertrophy
[23], providing further evidence of sigma-1R’s cardioprotective
role against hypertrophy. The molecular mechanisms for sigma-
1R-mediated cardioprotection against hypertrophy were eluci-
dated. In the above models, Akt phosphorylation, eNOS levels
and eNOS phosphorylation were decreased in cardiac hypertrophy,
while sigma-1R agonists (E2, DHEA, fluvoxamine) restored the
decrease [18,23–25]. Application of the sigma-1R antagonist N,
N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine
monohydrochloride (NE-100) abolished the agonist-induced Akt
and eNOS activation, further providing evidence of sigma-1R’s
stimulatory role in the Akt-eNOS pathway [24]. Specifically, treat-
ment with sigma-1R agonists promoted recovery of hypertrophy-
induced decrease in Akt phosphorylation at Ser473 in rat car-
diomyocytes, as well as decreased expression of eNOS and
Table 1
. Table summarising the results of the quality appraisal of the 23 papers. A total of 13 criteria were assessed, based on the quality checklist formulated by The Checklist of Review Criteria established by the Task Force of Academic
Medicine and the GEA-RIME Committee [22] was used. 22 out of 23 papers met at least 12 out of 13 criteria and were included in the study.
Paper Problem
statement,
conceptual
framework, and
research
question
Reference to
the literature
and
documentation
Relevance Research
design
Instrumentation,
data collection,
and quality
control
Population
and sample
Data
analysis
and
statistics
Reporting
of
statistical
analyses
Presentation
of results
Discussion
and
conclusion:
interpretation
Title,
authors
and
abstract
Presentation
and
documentation
Scientific
conduct
Total
criterla
met
Gao et al.,
2018 [59]
U U U U U U U U U U U U U 13
Qin et al.,
2018 [60]
U U U U U U U U U U U 11
Liu et al.,
2017 [61]
U U U U U U U U U U U U 12
Alam et al.,
2017 [49]
U U U U U U U U U U U U 12
Bao et al.,
2017 [62]
U U U U U U U U U U U U U 13
Shinoda
et al.,
2016 [27]
U U U U U U U U U U U U 12
Stracina
et al.,
2015 [63]
U U U U U U U U U U U U 12
Balasuriya
et al.,
2014 [51]
U U U U U U U U U U U U 12
Tagashira
et al.,
2014 [28]
U U U U U U U U U U U U 12
Tagashira
et al.,
2013 [29]
U U U U U U U U U U U U U 13
Amer et al.,
2013 [64]
U U U U U U U U U U U U 12
Delaunois,
et al.,
2012 [65]
U U U U U U U U U U U U U 13
Tagashira
et al.,
2011 [24]
U U U U U U U U U U U U U 13
Crottès et al.,
2011 [66]
U U U U U U U U U U U U 12
Novakova
et al.,
2010 [67]
U U U U U U U U U U U U U 13
Johannessen
et al.,
2010 [52]
U U U U U U U U U U U U 12
Tagashira
et al.,
2010 [23]
U U U U U U U U U U U U 12
Bhuiyan
et al.,
2010 [18]
U U U U U U U U U U U U 12
Bhuiyan and
Fukunaga,
2009 [25]
U U U U U U U U U U U U U 13
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R. Lewis et al. / IJC Heart & Vasculature 26 (2020) 100449 5decreased eNOS phosphorylation at Ser1177 [18,23–25]. These
suggest that sigma-1R stimulation of the Akt-eNOS pathway is a
key mechanism to explain its cardioprotective effects against
hypertrophy in murine models and cell cultures. Sigma-1R restora-
tion of IP3R-mediated mitochondrial ATP production was proposed
as another mechanism for cardioprotection against hypertrophy.
Sigma-1R directly interacts and stabilises IP3R2 channels found
on the mitochondrial-associated ER (SR) membrane (MAM) [27–
29]. Treatment with sigma-1R agonists such as pentazocine (an
opioid receptor modulator) and fluvoxamine leads to upregulation
of sigma-1R, promoting stabilisation of the sigma-1R/IP3R2 com-
plex on MAMs, allowing for Ca2+ transport into mitochondria and
hence ATP production [28]. The energy supplied by ATP production
promotes SERCA2a ATPase activity [28], thereby promoting Ca2+
storage and maintenance of heart contractile function. A third
mechanism for sigma-1R-mediated cardioprotection against
hypertrophy is via IP3R2- and RyR-mediated Ca2+ leakage into
cytosol, alleviating intracellular calcium overload. Sigma-1R inhi-
bits IP3R2 and RyR channels found on SR membranes. Fluvoxamine
and pentazocine treatment were found to be cardioprotective in
inhibiting cardiac hypertrophy and dysfunction via suppressing
intracellular Ca2+ overload by inhibiting IP3R2 and RyR-mediated
Ca2+ release from the SR [28,29].
Sigma-1R is also shown to regulate Ca2+ entry at both the
plasma membrane level, via K+ channels and voltage-sensitive
Ca2+ channels, and to modulate Ca2+ mobilisation from ER stores
[30,31]. A recent study in retinal ganglion cell line-5 showed that
sigma-1R activation contributes to reduction of calcium overload
by inhibiting calcium influx [31]. Taken together, a similar mecha-
nism may be used to explain the functional recovery of
angiotensin-II induced CM hypertrophy by fluvoxamine treatment
[18]: fluvoxamine-mediated activation of sigma-1R may alleviate
calcium overload, hence promoting cardiac remodelling and func-
tional recovery in terms of CM contraction and relaxation.
Sigma-1R has also been shown to be cardioprotective against
apoptosis after ischaemia/reperfusion injury. In a rat myocardial
ischaemia/reperfusion (I/R) model administering the selective
sigma-1R agonist, 2-(4-morpholinoethyl)-1-phenylcyclohexane-1
-carboxylate hydrochloride (PRE-084), to I/R-injured rats led to
better recovery of haemodynamic parameters such as left ventric-
ular pressure development and left ventricular systolic pressure.
Furthermore, PRE-084 treatment decreased the degree of myocar-
dial apoptosis, by increasing Bcl-2 and decreasing Bax levels. It is
proposed that this effect is due to sigma-1R activation of the
PI3K/Akt/eNOS pathway, which is shown to be stimulated by
sigma-1R in the heart [32], and known to be the most important
pathway for apoptotic regulation [33–35]. Given that apoptosis is
the major pathogenic mechanism of myocardial I/R injury
[36,37], and that myocardial cells are non-regenerative, this indi-
cates great potential for the future treatment of myocardial I/R
injuries with sigma-1R stimulation.
Lastly, sigma-1R is proposed to be cardioprotective against mal-
adaptive ER stress. Typically, pathological development in heart
disease can be a result of chronic stresses disturbing ER function,
including free radicals, ischaemia, hypoxia, elevated protein syn-
thesis and gene mutation. The result is a condition known as
‘‘ER-stress”, characterised by the accumulation of unfolded and
misfolded proteins [38,39]. While the traditional ER stress
response stimulates adaptive and pro-survival pathways to restore
ER homeostasis [40–42], chronic exposure to stress can lead to
maladaptive expression of C/EBP-homologous protein (CHOP)
[43,44], thereby inducing apoptosis [45–48]. Sigma-1R is shown
to be cardioprotective under conditions of tunicamycin-induced
ER stress by reducing CHOP expression in neonatal rat ventricular
cardiomyocytes. The molecular interaction likely lies between
Sigma-1R and IRE1a: Sigma-1R is shown to transiently and directly
Table 2
A summary table of the 22 research papers analysed following a systematic search protocol for papers including ‘‘sigma-1 receptor” and ‘‘cardiac”. For each paper, the methods,
materials, results, limitations and further work suggested are summarised.
Author(s) Material used Techniques used Results and discussion Limitations suggested by
authors
Further work suggested by
authors
Gao et al.,
2018 [59]
Adult male
Sprague-Dawley
rats (220-250g)
Intraperitoneal injection of
PRE-084 or saline, LAD
ligation to induce myocardial
ischaemia, followed by
reperfusion, haemodynamic
measurements, TUNEL assay,
Western blotting
Treatment with Sigma-1R
agonist PRE-084 increased
recovery of haemodynamic
function and reduced apoptosis,
after myocardial I/R injury;
cardioprotective mechanism
likely via Akt-eNOS pathway and
decreasing apoptosis via
changing expression of
apoptotic-related proteins
Animals pre-treated with
PRE-084 (vs in clinical setting,
they will be treated after MI).
Previous studies showed PRE-
084 protects the heart by
stimulating Sigma-1R in brain
Sigma-1R interacts with ion
channels, including Ca2+, K+,
Na+, Cl channels, potential
mechanisms to be elicited;
PRE-084 to treat myocardial
I/R injuries
Liu et al.,
2017 [61]
Homozygous
Sigma-1R KO
mice, HEK293
cells
CRISPR/Cas9, Western
blotting,
immunohistochemistry,
electrophysiology,
electroretinogram,
intravitreal injection
Sigma-1R selective ligands
potently inhibited Kv2.1
currents, but in a sig-R
independent manner, as the
ligands exerted similar effect in
WT and Sigma-1R KO cells
Therapeutic opportunities –
conciliating drug effects on
Sig-Rs and the Kv2.1 channel
Alam et al.,
2017 [49]
Primary neonatal
rat ventricular
cardiomyocytes
(NRCs) from 1 to
2-day old
Sprague-Dawley
rat pups
Adenovirus-mediated Sigma-
1R overexpression, siRNA-
mediated sigma-1R
knockdown, tunicamycin,
immunocytochemistry,
Western blotting,
immunoprecipitation, LDH
release assay
Sigma-1R found to mediate the
IRE1a-XBP1 response to ER
stress in cardiomyocytes.
Overexpression of sigma-1R led
to increase in IRE1a
phosphorylation, increase XBP1
expression and nuclear
localisation, decrease in CHOP
expression
Study the direct role of
Sigma-1R in specific ER-
response pathways; study
pathway-specific gene
activation programmes
in vivo in various
pathological conditions
Bao et al.,
2017 [62]
Neonatal rat
cardiomyocytes,
adult male
Sprague-Dawley
rats
Bioinformatic analysis, TAC,
echocardiography,
histological staining,
transfection, dual-luciferase
reporter assay,
immunofluorescence, qRT-
PCR, Western blotting
miR-297 negatively and directly
regulates Sigma-1R expression.
Increased miR-297 observed in
hypertrophic models, correlated
with decreasing Sigma-1R levels.
miR-297 promotes CM
hypertrophy by inhibiting the
expression of Sigma-1R and
activation of ER stress signalling,
specifically XBP1 and ATF4
pathways
Precise mechanism by which
Sigma-1R induces splicing of
Xbp1 by IRE1a not explored;
activation of ATF4 not
explored in the study
Sigma-1R and inhibition of
miR-297 as a potential
treatment for cardiac
hypertrophy
Shinoda
et al.,
2016 [27]
Neonatal rat
ventricular
cardiomyocytes
from Wistar rats,
ICR mice
TAC-induced hypertrophy,
ANGII-induced hypertrophy
mitochondrial staining,
immunocytochemistry,
Western blot, qRT-PCR,
echocardiography,
morphological analysis,
histological analysis, ATP
content assay, ratiometric
dyes for intracellular and
mitochondrial Ca2+
measurement, TUNEL
staining for apoptosis
Treating cardiomyocytes and
micewith haloperidol altered the
mitochondrial calcium transport
via inhibiting Sigma-1R
expression. This leads to
impaired mitochondrial ATP
production and hence adverse
cardiac remodelling and
impairment of cardiac function.
ATP supplementation with
sodium pyruvate rescues ATP
levels in haloperidol-treated TAC
mice and recovers cardiac
function.
Suggests supplementing
schizophrenic patients
treated with haloperidol
with ATP supplementation
(eg sodium pyruvate) may
prevent adverse effects on
cardiac function
Stracina
et al.,
2015 [63]
Guinea pigs Haloperidol administration,
qRT-PCR of Sigma-1R and
IP3R expression,
immunohistochemical
staining, Langendorff-
perfusion, ECG (to study QT
interval and detect
arrhythmia)
Increased expressionSigma-1R in
atrial cardiomyocytes in guinea
pigs exposed to haloperidol.
Increased signalling via Sigma-1R
and IP3 receptor occurred in
haloperidol-treated groups.
Chronic haloperidol
administration significantly
decreased heart rate over time.
Exposure to haloperidol
increased the QT interval,
suggested to be related to IKr
activity. Haloperidol in guinea
pig hearts increases gene
expression of Sigma-1R and
IP3Rs. This may lead to altered
calcium handling, such as
affecting the availability of
calcium ions in cardiomyocytes
which subsequently lowers the
arrhythmogenic threshold.
Further studies need to
understand how acute and
chronic haloperidol
treatment affects the IKr
current, calcium availability
and if its influences the co-
localisation of Sigma-1R and
IP3Rs.
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Table 2 (continued)
Author(s) Material used Techniques used Results and discussion Limitations suggested by
authors
Further work suggested by
authors
Balasuriya
et al.,
2014 [51]
tsA 201 cells
(HEK-293
subclone)
Cell culture, transient
transfection with DNA
encoding sigma-FLAG,
immunofluorescence, in situ
proximity ligation assay, AFM
imaging of isolated proteins,
extracellular HTRF
Sigma-1R was shown to promote
hERG protein expression within
the plasma membrane. Sigma-
1R ligands showed no effect on
hERG expression. Sigma-1R
likely binds to an immature
hERG protein, seems to occur in
the ER and its expression is
enhanced with Sigma-1R is co-
expressed, albeit this seems to
have no effect on its activation
within the cell. Sigma-1R seems
to reduce expression of mature
hERG in cells.
Studies into the interactions
with sigma-1R to
understand its mechanisms
of action with selective
ligands and cholesterol. With
a suggestion that hERG is
involved in cardiac
arrhythmias, a clearer
understanding of this
interaction may provide
potential therapeutic
approaches.
Tagashira
et al.,
2014 [28]
Adult male ICR
mice, neonatal rat
ventricular
cardiomyocytes
TAC, ANGII-treatment to
induce hypertrophy, RNAi by
siRNA, morphological
analysis of cells,
mitochondrial staining,
immunocytochemistry,
Western blotting, ratiometric
measurement of intracellular
and mitochondrial Ca2+ (by
FURA2 and pericam),
measurement of ATP content
in vitro and in vivo
Imbalance of Sigma-1R and
IP3R2 expression was found in
hypertrophic models, leading to
dysregulation of IP3R2 function
due to dissociation from Sigma-
1R. Fluvoxamine (Sigma-1R
agonist) leads to upregulation of
Sigma-1R, thereby (1) stabilising
the Sigma-1R/ IP3R2 complex on
MAMs, allowing for Ca2+
transport into mitochondria and
hence ATP production, as well as
(2) suppressing intracellular Ca2+
overload by inhibiting IP3R2 and
RyR-mediated Ca2+ release from
SR.
Further studies to define the
regulatory role of RyR-
mediated Ca2+ release into
cytosol by Sigma-1R, to
determine potential
interaction between Sigma-
1R and TRPCs in CMs,
explore mechanisms
underlying Sigma-1R
mediated inhibition of
fission or enhancement of
mitochondrial elongation
Tagashira
et al.,
2013 [29]
Female adult
Wistar rats,
primary culture
of neonatal rat
ventricular
cardiomyocytes
Bilateral ovariectomy,
abdominal aortic banding,
heart weight measurement,
qRT-PCR, histological
techniques (Masson’s
trichome staining),
haemodynamic
measurements,
immunohistochemistry,
ANGII treatment to induce
CM hypertrophy, cross-
linking and
immunoprecipitation,
Western blot, ATP content
measurement, intracellular
Ca2+ measurement using
FURA2
Pentazocine, a Sigma-1R agonist,
prevented downregulation of
Sigma-1R in hypertrophy.
Sigma-1R stimulation with
pentazocine was found to be
cardioprotective in inhibiting
cardiac hypertrophy and
dysfunction, by restoring IP3R-
mediated Ca2+ entry into
mitochondria and hence ATP
production, as well as inhibiting
RyR-mediated Ca2+ leakage into
cytoplasm.
Did not define the association
regions between Sigma-1R
and RyR2 (- to be done in
future studies)
Studies should identify the
mechanism where RyR2-
mediated calcium release by
sigma-1R is regulated and
the associated molecular
regions between these two
receptors. Further studies
required to identify
mechanisms underlying
regulation of RyR2-mediated
Ca2+ release into cytosol by
Sigma-1R.
Amer et al.,
2013 [64]
Endothelial cells
(from human
saphenous vein)
and HEK-293
cells
Application of Sigma-1R
agonist and antagonist, siRNA
to decrease Sigma-1R
expression, fluorescence
microscopy, measurement of
intracellular Ca2+, whole-cell
patch clamp
Multiple Sigma-1R agonists and
antagonists applied with
different results. Some ligands
were inhibitory, some were
stimulatory while some did not
exert effects on transient
calcium channels. Specifically,
BD1047/BD1063 and 4-IBP are
inhibitors of
receptor/chemically-activated
calcium entry channels. They
seem to act directly and
independently of Sigma-1R.
Sigma-1R ligands exert
pharmacologically effect
rather independently of
Sigma-1R: important
information for developing
therapeutic drugs
Delaunois,
et al.,
2012 [65]
Conscious
tethered
Sprague-Dawley
rats with intra-
arterial catheter
and tethers
Repeated handling and
dosing with sigma-1R
agonists and antagonists, HR,
SBP, DBP, MAP recorded
Endogenous Sigma-1R activation
may contribute to stress-induced
tachycardia. 3 out of 4 agonists
decrease this phenomenon;
antagonists have no effect.
Neither had effect on HR during
and after the dosing procedure.
Sigma-1Rs are involved in the
stress response but not in its
initiation. Findings suggest that
mechanisms underlying HR
regulation involving Sigma-1Rs
differ according to different
conditions.
Did not evaluate the
anxiolytic properties of the
Sigma-1R ligands
Further studies should look
at the possible link between
the baroreflex function of the
heart and sigma-1R
activation. Studies on cardiac
contractility in vivo should
be assessed to understand
the effects of drugs acting on
Sigma-1Rs.
(continued on next page)
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Table 2 (continued)
Author(s) Material used Techniques used Results and discussion Limitations suggested by
authors
Further work suggested by
authors
Tagashira
et al.,
2011 [24]
Female Wistar
rats
Bilateral ovariectomy, TAC
(abdominal aorta) in rats, oral
DHEA and subcutaneous E2
administration,
haemodynamic
measurements, Western blot,
qRT-PCR, heart weight
measurement
PO-induced hypertrophy
reduced Sigma-1R expression;
DHEA and E2 cardioprotective,
act via increasing p-Akt, eNOS
and p-eNOS. DHEA increased
Sigma-1R (mRNA and protein),
E2 did not. DHEA likely act via
Sigma-1R, while E2 does not
DHEA(S) not found normally
circulating in mice or rats.
DHEA administered in the
experiment is of a higher
concentration that normal
human circulating levels.
DHEA may have acted via
other Sigma-1R-independent
mechanisms, such as PPARa.
To determine the localisation
of Sigma-1R in
cardiomyocytes after DHEA
treatment (to elicit if the
mechanism of action is via
stabilising IP3R); DHEA as
potential hormonal therapy
candidate as compared to
estrogens (E2)
Crottès et al.,
2011 [66]
K562 and HEK
293 cell lines,
Xenopus laevis
cDNA preparation, patch
clamp, double electrode
voltage clamp, adhesion
experiments, Western blot
(hERG, Sigma-1R), shRNA
lentiviral transduction, co-
immunoprecipitation, flow
cytometry, transfection of
HEK 293 cells with hERG1
and Sigma-1R, qRT-PCR, pulse
chase
In HEK cells expressing hERG
and sig1R, both proteins co-
immunoprecipitate, indicating
physical association. Sigma-1R
expression enhances hERG
protein maturation and stability.
Sigma-1R controls hERG
expression through the
regulation of subunit trafficking
activity
Sigma-1R to be considered as
a new pharmacological
target to reduce membrane
signalling complexes activity
with implications in cancer
treatment
Novakova
et al.,
2010 [67]
Cardiomyocytes Chronic administration of
haloperidol, Langendorff-
perfusion, ECG, qRT-PCR,
Western blot
Haloperidol treatment affects
expression of IP3R1 and 2 in
atria but not in ventricles.
Increase in IP3R may be involved
in arrhythmia, but increase is
likely due to upregulation at
neuronal level rather than
cardiomyocyte level
Did not prove the direct link
between QTc interval changes
and arrhythmias
Further verification needed
regarding the theory that
increase in IP3R gene
expression in neuronal cells
rather than cardiomyocytes
contribute to
arrhythmogenesis
Johannessen
et al.,
2010 [52]
HEK293 cells siRNA to knockdown Sigma-
1R, electrophysiology, drug
application of both agonists
and antagonists, Sig-R
competitive binding assays,
photoaffinity labelling
Progesterone binds to Sigma-1R
and Sig-2Rs, and blocks
photolabeling of these 2
receptors in HEK293 cells;
Progesterone inhibits the
channel modulation effects of
Sig-R ligands. Progesterone
binding to Sig-Rs block Sig-R-
mediated modulation of a
voltage-gated ion channel
Since Sig-Rs modulate a wide
range of ion channels,
necessary to test other
channels for Sig-R/
progesterone interactions in
the future. Furthermore,
other steroids that bind to
Sig-R, such as testosterone,
DHEA and cholesterol should
also be tested
Tagashira
et al.,
2010 [23]
Adult male ICR
mice and murine
neonatal
ventricular
myocytes
TAC (aortic arch), oral
fluvoxamine and paroxetine
maleate, heart weight
measurement,
echocardiography, Western
blot, morphological analysis,
si-RNA transfection, Western
blot
Fluvoxamine treatment protects
against TAC-induced cardiac
hypertrophy and ANG-II induced
cardiomyocyte hypertrophy, via
increased expression of sigma-
1R, likely mediated by the Akt-
eNOS signalling pathway
Mechanism in which
fluvoxamine treatment
causes upregulation/
stabilisation of Sigma-1R is
to be elucidated; to
understand how chronic
fluvoxamine treatment
affects Sigma-1R; potential
for development of a new
class of antihypertrophic
drugs
Bhuiyan
et al.,
2010 [18]
Adult male and
female Wistar
rats
Bilateral ovariectomy in
female rats, abdominal aortic
banding, oral fluvoxamine
and NE-100 administration,
haemodynamic
measurements, Western blot,
heart weight measurement,
immunohistochemistry
Sigma-1R expression in the heart
can attenuate PO-induced
hypertrophy in ovariectomised
rats; Sigma-1R agonist
fluvoxamine treatment protects
against PO-induced hypertrophy
via upregulating Sigma-1R and
stimulating Sigma-1R mediated
Akt-eNOS signalling
To understand how chronic
fluvoxamine treatment
affects Sigma-1R; potential
for development of a new
class of antihypertrophic
drugs
Bhuiyan and
Fukunaga,
2009 [25]
Female Wistar
rats
Bilateral ovariectomy,
abdominal aortic banding in
rats, oral DHEA
administration,
haemodynamic
measurements, Western blot,
heart weight measurement
Sigma-1R expression in the heart
can attenuate PO-induced
hypertrophy in ovariectomised
rats; Sigma-1R agonist DHEA
treatment protects against PO-
induced hypertrophy via
upregulating Sigma-1R amd
stimulating Sigma-1R mediated
Akt-eNOS signalling
DHEA(S) not found normally
circulating in mice or rats;
administered DHEA in the
experiment is also higher
concentration than normal
human circulating levels
Potential for development of
a new class of
antihypertrophic drugs
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Table 2 (continued)
Author(s) Material used Techniques used Results and discussion Limitations suggested by
authors
Further work suggested by
authors
Johannessen
et al.,
2009 [53]
Neonatal mouse
cardiac myocyte
siRNA to knockdown Sigma-
1R, electrophysiology, drug
application of both agonists
and antagonists, photoaffinity
labelling
Sigma-1R ligands (SKF-10047,
pentazocine, haloperidol and
ditoylguanidine) reversibly
inhibited Nav1.5 in HEK293 and
COS-7 cells, also inhibited Na+
current in neonatal mouse
cardiac myocytes; Sig-Rs inhibits
Nav1.5 channels and thus the
INa, likely inhibit contractility
and rhythmicity
Other research showed
Sigma-1R to inhibit inwardly
rectifying K+ and hERG K+
channels, which will
stimulate contractility and
rhythmicity, while inhibiting
Na+ channels have the
opposite effect – investigate
how the opposing effects are
resolved. Potential future
applications for anti-
arrhythmics
Fontanilla
et al.,
2009 [68]
HEK293 cells Competitive binding assays,
electrophysiology, drug
application, photoaffinity
labelling
DMT bound to sigma-1R,
inhibited Na+ channels in native
cardiac myocytes and
heterologous cells that express
sigma-1Rs. DMT induced
hypermobility in WT mice but
not in sigma-1R knock-down
mice, suggesting that DMT is an
endogenous agonist for Sigma-
1R
Zhang and
Cuevas,
2005 [58]
Neonatal rat
intracardiac
ganglia
Electrophysiological
techniques (whole-cell patch-
clamp)
Stimulation of sigma-1Rs inhibit
multiple voltage-gated K+
channel subtypes via direct
coupling (delayed outwardly
rectifying potassium channels,
large conductance Ca2+-sensitive
K+ channels, and the M-channel)
and depresses excitability in
intracardiac neurons
Inhibition of voltage-gated K+
channels alone cannot
explain the complete block of
action potential firing at high
concentrations of sig ligands
– sig-Rs likely to affect other
channel types that affect AP
firing (e.g. voltage-gated Na+
channels)
Sig-R modulation of other
mechanisms of Ca2+ entry or
homeostasis must be
examined to confirm a direct
effect of sigma-1R on Ik(Ca)
Zhang and
Cuevas,
2002 [57]
Neonatal rat
intracardiac
ganglia
RT-PCR and gel
electrophoresis of total RNA
extracts and single-cell RNA
extracts, electrophysiological
studies (voltage-clamp using
perforated-patch
configuration of whole cell
patch-clamp recording
technique,
electrophysiological
methods), bath application of
sigma-1R agonists
Sigma-1Rs found to be expressed
in neonatal rat intracardiac
neurons. Application of Sig-R
agonists inhibited all Ca2+
channel subtypes in the neurons.
Sig-R activation depressed the
peak Ca2+ channel current,
increased the rate of Ca2+
channel inactivation, and shifted
the voltage-dependence of
steady-state inactivation and
activation towards more
negative potentials. However,
modulation of Ca2+ channel
activity is likely only via the
Sig-2R
Function of Sigma-1R in
autonomic neurons remains
to be elucidated.
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sation and phosphorylation [50]. This results in the alternative
splicing of X-box binding protein 1 (XBP1) into a more stable form,
XBP1 spliced (XBP1s), which localises to the nucleus and inhibits
CHOP expression, suppressing ER-stress-induced cellular toxicity.
It is thus worth exploring the therapeutic potential of sigma-1R-
dependent activation of the IRE1a-XBP1 pathway.6. Sigma-1R modulation of cardiac ion channels
Sigma-1R is known to interact with many ion channels in the
nervous system. Various studies have thus investigated if Sigma-
1R exerts modulatory effect on potassium, sodium and calcium
ion channels in the cardiovascular system. Sigma-1R was shown
to promote human Ether-à-go-go-Related Gene (hERG) protein
expression within the plasma membrane. The hERG is a compo-
nent of the rapidly-activating delayed rectifier potassium channel,
which is involved in long QT syndrome, a disorder associated with
increased risk of ventricular arrthymias. Co-precipitation of hERG
and Sigma-1R was detected, indicating direct interaction betweenthese two proteins. However, while Balasuriya et al., 2014 [51] pro-
posed that Sigma-1R binds to an immature hERG in the ER and
reduces expression of mature hERG, Johannessen et al, 2009, sug-
gested that sigma-1R expression enhances hERG protein matura-
tion and stability, by regulating subunit trafficking activity of
hERG [52]. Clearly, there is conflicting evidence on the effect of
sigma-1R on hERG, indicating room for further studies.
Sigma-1R ligands including N-allylnormetazocine (NANM/SKF-
10047); a synthetic opioid analgesic of the benzomorphan family,
pentazocine; an opioid analgesic, haloperidol; an antipsychotic
drug with a strong dopamine receptor antagonism and ditoyl-
guanidine were found to reversibly inhibit NaV1.5 in HEK293 and
COS-7 cells, and inhibit sodium currents in neonatal mouse cardiac
myocytes. NaV1.5 is crucial for cardiac action potential induction.
The inhibition of NaV1.5 channels has subsequent effects on INa
and thus cardiac contractility and rhythmicity [53,54].
Perturbations in calcium signalling occur during cardiac hyper-
trophy, where cardiac myocyte phenotype changes resulting in
altered electrical signalling. Calcium influx via the STIM1/Orai
complex is one mechanism by which the cardiac action potential
is altered in the hypertrophic heart; inhibition of this calcium entry
Fig. 2. Experimental platforms used Summary of the different experimental platforms used by the 22 papers to study the effect of sigma-1R in relation to the cardiovascular
system. (a) Number of papers that used each of the 3 types of experimental platforms and (b) number of papers that used each of the specific experimental platforms.
Fig. 3. Experimental techniques used Summary of the different experimental techniques used by the 22 papers to study the effect of sigma-1R in relation to the
cardiovascular system.
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Fig. 4. Summary of the main roles of the sigma-1R in relation to the cardiovascular system.
R. Lewis et al. / IJC Heart & Vasculature 26 (2020) 100449 11pathway has been shown to improve cardiac function [55]. Sigma-
1R provides a novel method for inhibition of this pathway, as its
activation also inhibits store-operated calcium entry [56].7. Sigma-1R modulation of ionic currents in intracardiac
neurons
Sigma-1Rs were found to be expressed in neonatal rat intracar-
diac neurons [57]. Application of sigma-R agonists such as
haloperidol and (+)-pentazocine inhibited all Ca2+ channel sub-
types in the neurons. Calcium channel activity is critical for trans-
duction of action potentials in these neurons. Sigma-R activation
also depressed the peak Ca2+ channel current, increased the rate
of Ca2+ channel inactivation, and shifted the voltage-dependence
of steady-state inactivation and activation towards more negative
potentials. However, pharmacological properties suggest that
modulation of Ca2+ channel activity is likely only via the sigma-
2R [29]. Further studies on the effect of sigma-1R on other ion
channels suggested that activation of sigma-1Rs reversibly blocked
numerous potassium channels in intracardiac neurons [58]. These
channels include delayed outwardly rectifying potassium chan-
nels, large conductance Ca2+-sensitive K+ channels, and the M-
channel. Experimental evidence suggests direct coupling of
sigma-1R receptors to these K+ channels. The effect of sigma-1R
activation on these K+ channels led to intracardiac neuronal depo-
larisation and decreased excitability. This may hence reduce
parasympathetic input to the heart and impact cardiovascular
function. These results have implications on drug treatments that
act on sigma-1Rs, including haloperidol which is commonly used
as an anti-psychotic to treat schizophrenia, and may explain the
side effects of such drug treatments on cardiovascular function.
Various studies have shown sigma-1R to be cardioprotective
against hypertrophy, and we suggest further work into this area.
Numerous pharmacological agents including endogenous and
synthetic agonists have also been identified. Anti-hypertrophicsigma-1R agonists identified in the 22 studies include: pentazocine
[29], DHEA [24,25] and fluvoxamine [18,26,28]. These agonists
were shown to be cardioprotective against hypertrophy in TAC-
induced hypertrophic murine models and in ANGII-induced hyper-
trophic cardiomyocyte tissue culture models. Further work into
these specific ligands is encouraged for the potential development
of novel drug candidates against cardiac hypertrophy. We also sug-
gest further research into the role of sigma-1R in ER stress. Sigma-
1R was found to have a role in the adaptive cardiomyocyte ER
stress response by reducing CHOP expression by increasing XBP1s
[49], hence reducing CHOP-induced apoptosis. However, in a sepa-
rate study, Sigma-1R was found to inhibit the XBP1 pathway,
resulting in cardioprotection against hypertrophy (Bao et al.,
2017). The conflicting effects of sigma-1R on XBP1 expression
may be due to the inability of these studies to directly investigate
the molecular mechanism of sigma-1R in the ER stress response
pathways. Thus, while both studies showed sigma-1R to be cardio-
protective, they presented conflicting evidences regarding the
effect of sigma-1R on the XBP1 ER-stress response pathway, which
needs to be further explored.
Sigma-1R has been widely studied in the brain and central ner-
vous system, but its role in the heart and cardiovascular system has
not been well elucidated. Recent studies have shown sigma-1Rs to
be implicated in various pathways in the cardiovascular system.
These include cardioprotection, modulation of ion channels and
modulating intracardiac neuron excitability. The cardioprotective
role of sigma-1R in hypertrophic models have been extensively
studied, and various molecular mechanisms have been proposed
to explain the anti-hypertrophic effects of administering
sigma-1R agonists. These include: (1) stimulation of the Akt-
eNOS pathway, (2) restoration of IP3R-mediated mitochondrial
ATP production, (3) reduction of intracellular calcium by inhibition
of IP3R2 and RyR channels and (4) inhibition of ER stress signalling.
Furthermore, sigma-1R’s role in reducing cellular toxicity and
apoptosis in reducing ER stress have also been recently investi-
gated. Apart from cardioprotective properties, sigma-1R is shown
12 R. Lewis et al. / IJC Heart & Vasculature 26 (2020) 100449to interact with numerous cardiac ion channels, including K+, Na+
and Ca2+ channels, such as IP3R and RyR channels that have impli-
cations in cardiomyocyte calcium handling. Studies have also
looked into the role of sigma-1R in intracardiac neurons, with
implications in modulating cardiovascular activity via alteration
of peripheral nervous system excitability. These studies reflect
the diverse functions of the sigma-1R (Fig. 4). Based on results of
this systematic review, the sigma-1R appears to have a clear role
in cardioprotection and should be explored as a potential drug tar-
get for cardiac pathologies.References
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